WO2004075863A3 - Cxcr3 antagonists - Google Patents

Cxcr3 antagonists Download PDF

Info

Publication number
WO2004075863A3
WO2004075863A3 PCT/US2004/005960 US2004005960W WO2004075863A3 WO 2004075863 A3 WO2004075863 A3 WO 2004075863A3 US 2004005960 W US2004005960 W US 2004005960W WO 2004075863 A3 WO2004075863 A3 WO 2004075863A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
diseases
useful
treatment
cxcr3 antagonists
Prior art date
Application number
PCT/US2004/005960
Other languages
French (fr)
Other versions
WO2004075863A2 (en
Inventor
Tassie L Collins
Michael G Johnson
Ji Ma
Julio C Medina
Shichang Miao
Manfred Schneider
George R Tonn
Original Assignee
Tularik Inc
Tassie L Collins
Michael G Johnson
Ji Ma
Julio C Medina
Shichang Miao
Manfred Schneider
George R Tonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc, Tassie L Collins, Michael G Johnson, Ji Ma, Julio C Medina, Shichang Miao, Manfred Schneider, George R Tonn filed Critical Tularik Inc
Priority to EP04715730A priority Critical patent/EP1603896A2/en
Publication of WO2004075863A2 publication Critical patent/WO2004075863A2/en
Publication of WO2004075863A3 publication Critical patent/WO2004075863A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
PCT/US2004/005960 2003-02-27 2004-02-27 Cxcr3 antagonists WO2004075863A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04715730A EP1603896A2 (en) 2003-02-27 2004-02-27 Cxcr3 antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45115703P 2003-02-27 2003-02-27
US60/451,157 2003-02-27

Publications (2)

Publication Number Publication Date
WO2004075863A2 WO2004075863A2 (en) 2004-09-10
WO2004075863A3 true WO2004075863A3 (en) 2004-12-09

Family

ID=32927703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005960 WO2004075863A2 (en) 2003-02-27 2004-02-27 Cxcr3 antagonists

Country Status (3)

Country Link
US (1) US20040242498A1 (en)
EP (1) EP1603896A2 (en)
WO (1) WO2004075863A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
TW200714610A (en) * 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
WO2007002701A2 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
US8367052B2 (en) 2007-03-26 2013-02-05 General Regeneratives Holdings Inc. Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
US9095591B2 (en) * 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083143A1 (en) * 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68

Also Published As

Publication number Publication date
US20040242498A1 (en) 2004-12-02
EP1603896A2 (en) 2005-12-14
WO2004075863A2 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2007062175A3 (en) Spiro-substituted tricyclic heterocycles cxcr3 antagonists
WO2007002701A3 (en) Anti-inflammatory aryl nitrile compounds
EA200300663A1 (en) CXCR3 ANTAGONISTS
WO2004075863A3 (en) Cxcr3 antagonists
IL245462A0 (en) Humanized anti-cmet antagonists
EG24829A (en) Process for the conversion of heavy charges such as heavy crude oils and distillation residues.
WO2005113513A3 (en) Aryl sulfonamides
MX2007000051A (en) Fused pyrimidine derivatives and compositions thereof as cxcr3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases.
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
MX2007002675A (en) Humanized anti-beta7 antagonists and uses therefor.
WO2005048935A3 (en) Methods of modulating immunity
BG108857A (en) Glutaminyl based dpiv inhibitors
WO2005020899A3 (en) Substituted cycloalkyamine derivatives as modulators of chemokine receptor activity
WO2006058236A3 (en) Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2005046603A3 (en) Pyridine compounds
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2006012492A8 (en) Compositions and methods for viscosupplementation
WO2005012243A3 (en) Substituted indole-o-glucosides
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004715730

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004715730

Country of ref document: EP